AbCellera Biologics
ABCL
9.69
-0.78
-7.45%
AbCellera Biologics
US · ABCL
#2215 by market cap
Listed 2020
9.69
-0.78
-7.45%
Periodic snapshot; not a real-time feed.
· 2026-11-20 19:59
Recent news
-
Rating change
Cantor Fitzgerald Maintains AbCellera Biologics(ABCL.US) With Buy Rating, Raises Target Price to $12\u5e02\u573a\u8d44\u8baf · 2026/8/6
-
Rating change
Stifel Maintains AbCellera Biologics(ABCL.US) With Buy Rating, Raises Target Price to $9\u5e02\u573a\u8d44\u8baf · 2026/8/6
-
Rating change
J.P. Morgan Initiates AbCellera Biologics(ABCL.US) With Buy Rating, Announces Target Price $17\u5e02\u573a\u8d44\u8baf · 2026/9/29
-
Rating change
JonesTrading Maintains AbCellera Biologics(ABCL.US) With Buy Rating, Raises Target Price to $25\u5e02\u573a\u8d44\u8baf · 2026/8/11
-
A Quick Look at Today's Ratings for AbCellera Biologics(ABCL.US), With a Forecast Between $14 to $25\u5e02\u573a\u8d44\u8baf · 2026/11/11
-
Rating change
Truist Financial Maintains AbCellera Biologics(ABCL.US) With Buy Rating, Maintains Target Price $30\u5e02\u573a\u8d44\u8baf · 2026/9/2
-
Rating change
Truist Financial Maintains AbCellera Biologics(ABCL.US) With Buy Rating\u5e02\u573a\u8d44\u8baf · 2026/8/10
-
Rating change
Piper Sandler Maintains AbCellera Biologics(ABCL.US) With Buy Rating, Maintains Target Price $12\u5e02\u573a\u8d44\u8baf · 2026/8/7
-
Rating change
Piper Sandler Maintains AbCellera Biologics(ABCL.US) With Buy Rating, Cuts Target Price to $12\u5e02\u573a\u8d44\u8baf · 2026/7/31
-
Jefferies Initiates AbCellera Biologics(ABCL.US) With Buy Rating, Announces Target Price $21\u5e02\u573a\u8d44\u8baf · 2026/10/30
-
Rating change
JonesTrading Maintains AbCellera Biologics(ABCL.US) With Buy Rating, Maintains Target Price $13\u5e02\u573a\u8d44\u8baf · 2026/7/30
-
Rating change
Cantor Fitzgerald Maintains AbCellera Biologics(ABCL.US) With Buy Rating, Raises Target Price to $11\u5e02\u573a\u8d44\u8baf · 2026/7/17
-
Rating change
Goldman Sachs Initiates AbCellera Biologics(ABCL.US) With Hold Rating, Announces Target Price $13\u5e02\u573a\u8d44\u8baf · 2026/9/24
-
Rating change
JonesTrading Maintains AbCellera Biologics(ABCL.US) With Buy Rating, Maintains Target Price $25\u5e02\u573a\u8d44\u8baf · 2026/9/28
-
Rating change
TD Cowen Maintains AbCellera Biologics(ABCL.US) With Buy Rating\u5e02\u573a\u8d44\u8baf · 2026/8/6
-
Rating change
BMO Capital Maintains AbCellera Biologics(ABCL.US) With Buy Rating, Raises Target Price to $15\u5e02\u573a\u8d44\u8baf · 2026/8/12
-
UBS Initiates AbCellera Biologics(ABCL.US) With Buy Rating, Announces Target Price $18\u5e02\u573a\u8d44\u8baf · 2026/11/13
-
Stifel Maintains AbCellera Biologics(ABCL.US) With Buy Rating, Raises Target Price to $14\u5e02\u573a\u8d44\u8baf · 2026/11/10
-
BMO Capital Maintains AbCellera Biologics(ABCL.US) With Buy Rating, Maintains Target Price $15\u5e02\u573a\u8d44\u8baf · 2026/11/10
-
Rating change
Truist Financial Maintains AbCellera Biologics(ABCL.US) With Buy Rating, Announces Target Price $30\u5e02\u573a\u8d44\u8baf · 2026/8/12
-
Rating change
Truist Financial Maintains AbCellera Biologics(ABCL.US) With Buy Rating, Announces Target Price $12\u5e02\u573a\u8d44\u8baf · 2026/5/22
-
Rating change
BMO Capital Maintains AbCellera Biologics(ABCL.US) With Buy Rating, Maintains Target Price $7\u5e02\u573a\u8d44\u8baf · 2026/6/18
-
Rating change
BMO Capital Maintains AbCellera Biologics(ABCL.US) With Buy Rating, Maintains Target Price $15\u5e02\u573a\u8d44\u8baf · 2026/8/18
-
Rating change
Analysts Offer Insights on Healthcare Companies: Alumis Inc. (ALMS) and AbCellera Biologics (ABCL)TipRanks · 2026/7/16
-
Rating change
Stifel Maintains AbCellera Biologics(ABCL.US) With Buy Rating, Raises Target Price to $8\u5e02\u573a\u8d44\u8baf · 2026/5/12
Headlines are aggregated automatically and are not independently verified or edited by our team.
Quote time 2026-11-20 19:59:30 · For reference only, not investment advice and not tailored to your situation.
AbCellera Biologics discussion 0 comments